Physician profile
Stuart D Segal
NPI 1508879354
$160,174.85
in general payments reported to CMS, 2019-2025
31 companies · $24K in 2025
The $24K reported for 2025 was more than what 93% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $29K · 2020: $28K · 2021: $17K · 2022: $29K · 2023: $14K · 2024: $19K · 2025: $24K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $40K · Travel and Lodging: $8,845 · Food and Beverage: $7,266 · Consulting Fee: $515 · Education: $110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $40,495.00 |
| Travel and Lodging | $8,845.12 |
| Food and Beverage | $7,265.66 |
| Consulting Fee | $515.00 |
| Education | $109.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $104,651.66 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Lilly USA, LLC | $38,444.23 | 2019-2023 | Taltz |
| Amgen INC. | $8,548.90 | 2019-2025 | Otezla, Tavneos, Krystexxa |
| Novartis Pharmaceuticals Corporation | $2,268.13 | 2019-2025 | |
| Pfizer INC. | $794.67 | 2019-2025 | |
| Glaxosmithkline, LLC. | $638.69 | 2019-2025 | Benlysta, Nucala |
| Radius Health, INC. | $566.00 | 2019-2025 | Tymlos |
| Genzyme Corporation | $499.46 | 2019-2023 | |
| Horizon Therapeutics Plc | $401.22 | 2019-2021 | |
| Ucb, INC. | $321.89 | 2019-2025 | Bimzelx, Cimzia |
| Mallinckrodt Enterprises LLC | $302.74 | 2019 | |
| Celgene Corporation | $301.91 | 2019 | |
| Mallinckrodt Hospital Products INC. | $298.45 | 2020-2025 | Acthar |
| Aurinia Pharma U.S., INC. | $298.27 | 2022-2025 | Lupkynis |
| E.R. Squibb & Sons, L.L.C. | $273.78 | 2019-2020 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $266.14 | 2019-2025 | Tremfya |
| Genentech USA, INC. | $263.73 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $257.40 | 2022-2024 | Saphnelo |
| Depuy Synthes Sales INC. | $200.27 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $149.90 | 2019-2025 | Jardiance, Ofev |
| Ferring Pharmaceuticals INC. | $77.64 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $74.06 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $54.99 | 2023 | |
| Novo Nordisk INC | $46.80 | 2025 | Ozempic |
| Travere Therapeutics, INC. | $41.60 | 2023-2025 | |
| Medexus Pharma, INC. | $27.03 | 2019 | |
| Sandoz INC. | $26.74 | 2025 | Jubbonti |
| Chiesi USA, INC. | $20.92 | 2025 | Elfabrio |
| Alexion Pharmaceuticals, INC. | $20.46 | 2019 | |
| Amicus Therapeutics, INC. | $18.69 | 2025 | |
| Ardelyx, INC. | $18.48 | 2025 | Ibsrela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stuart Segal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.